Rating Change
Wells Fargo analysts upgraded Editas Medicine, Inc. (NASDAQ:EDIT) from Equal-Weight to Overweight on October 08, 2026.
upgradeNASDAQ:EDIT
Editas Medicine, Inc. (EDIT) Upgraded to Overweight at Wells Fargo
Wells Fargo analysts upgraded Editas Medicine, Inc. (NASDAQ:EDIT) from Equal-Weight to Overweight on October 08, 2026.
At publication ·
What changed
Editas Medicine, Inc. (NASDAQ:EDIT) · upgrade
- Firm
- Wells Fargo
- Rating
- Equal-Weight to Overweight
- Price at event
- $2.84
- Market capitalization
- $217.7M
At a glance
Key takeaways
- Wells Fargo upgraded Editas Medicine from Equal-Weight to Overweight on October 8, 2026, suggesting analysts see improved fundamentals or favorable risk-reward.
Market Context
Editas Medicine, Inc. operates in the Healthcare sector. The stock currently trades at $2.84 with a market capitalization of $217.7M.
Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Wells Fargo's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Editas Medicine, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 08, 2026 | Wells Fargo | Overweight | N/A |
| Sep 23, 2026 | Guggenheim | Buy | N/A |
| Aug 18, 2026 | Ladenburg Thalmann | Buy | N/A |
| May 05, 2026 | Chardan Capital | Buy | N/A |
| Mar 10, 2026 | Jones Trading | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View EDIT Stock Page
Frequently Asked Questions
What does the Overweight rating mean for EDIT?
A rating of Overweight from Wells Fargo reflects the analyst's outlook on Editas Medicine, Inc. (NASDAQ:EDIT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the EDIT forecast page.